-
UPDATE: Bank of America Merrill Lynch Increases PO on Idenix Pharmaceuticals to $9
Tuesday, July 26, 2011 - 8:35am | 113Bank of America Merrill Lynch is out with its report today on Idenix Pharmaceuticals (NASDAQ: IDIX), increasing its PO from $6 to $9. In a note to clients, Bank of America Merrill Lynch writes, "We are increasing our PO from $6 to $9 for IDIX ahead of an important binary event in 4Q (est. Nov),...
-
Avanir Pharmaceuticals Provides "Several Positive Developments" on European Regulatory Filing for NUEDEXTA
Tuesday, July 26, 2011 - 8:33am | 301Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced several positive developments regarding its anticipated European regulatory filing of NUEDEXTA® (dextromethorphan hydrobromide and quinidine sulfate) capsules for the treatment of pseudobulbar affect. On July 22, 2011, company officials...
-
Aastrom Announces Agreement From FDA on Special Protocol Assessment for Phase 3 Clinical Trial in No-Option Critical Limb Ischemia Patients
Tuesday, July 26, 2011 - 7:52am | 61Aastrom Biosciences, Inc. (Nasdaq: ASTM) today announced that it has reached agreement with the U.S. Food and Drug Administration on the Special Protocol Assessment for the design of the Phase 3 REVIVE-CLI clinical trial of ixmyelocel-T, the company's expanded multicellular therapy, in patients...
-
Dyax Corp. and Kadmon Corporation Announce Antibody Library License Agreement
Tuesday, July 26, 2011 - 7:44am | 86Dyax Corp. (NASDAQ: DYAX) and Kadmon Corporation, LLC announced today that Dyax has granted Kadmon a non-exclusive license to Dyax's proprietary “gold-standard” antibody phage display libraries for the discovery and development of therapeutic antibodies. Dyax's human antibody phage libraries...
-
Interim Data from Phase 2 Study of Combination Regimen Including VX-222
Tuesday, July 26, 2011 - 7:36am | 331Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced interim results from ZENITH, an ongoing Phase 2 study designed to assess the safety, tolerability and efficacy of multiple 12- and 24-week response-guided treatment regimens with VX-222 (400 mg or 100 mg), its lead polymerase...
-
Vertex Reports First data from Phase 2 Study of Combination Regimen Showing Potential for Viral Cure in Many Patients with a 12-week Combination Regimen of Multiple Direct-Acting Antivirals
Tuesday, July 26, 2011 - 7:36am | 236Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced interim results from ZENITH, an ongoing Phase 2 study designed to assess the safety, tolerability and efficacy of multiple 12- and 24-week response-guided treatment regimens with VX-222 (400 mg or 100 mg), its lead polymerase...
-
Bank of America Raises PO On Idenix Pharmaceuticals To $9
Tuesday, July 26, 2011 - 7:27am | 28Bank of America has raised the price objective on Idenix Pharmaceuticals (NASDAQ: IDIX) from $6 to $9 and maintains its Buy rating.
-
European Medicines Agency Accepts Vanda Pharmaceuticals Inc.'s Marketing Authorization Application For Oral Iloperidone Tablets
Tuesday, July 26, 2011 - 7:08am | 156Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) announced today that the European Medicines Agency accepted for evaluation Vanda's Marketing Authorization Application for oral iloperidone tablets. Iloperidone is an atypical antipsychotic for the treatment of schizophrenia in adults. "The submission in...
-
Earnings Scheduled For July 26
Tuesday, July 26, 2011 - 4:47am | 507Lockheed Martin Corporation (NYSE: LMT) is projected to report its Q2 EPS at $1.93 on revenue of $11.42 billion. Ford Motor Company (NYSE: F) is estimated to report its Q2 earnings at $0.60 per share on revenue of $31.59 billion. Eastman Kodak Company (NYSE: EK) is expected to report a Q2 loss...
-
Stocks to Watch for Tuesday 7/26/2011: Fresh 52 Week Highs and Lows
Tuesday, July 26, 2011 - 4:07am | 1751Stocks trading at or near 52-week highs and lows provide excellent trading opportunities, as volatility tends to increase at such levels and entry/exit points become more defined. The following stocks hit new 52-week highs in Monday's trading session (listed from highest total volume to lowest):...
-
Benzinga's Top ETF Decliners, July 25th (SOXL, URTY, DRN, XBI)
Monday, July 25, 2011 - 8:10pm | 186Direxion Daily Semiconductor Bull 3X Shares (NYSE: SOXL) fell 3.82% on Monday as Teradyne, Inc. (NYSE: TER) lost 2.52%, and Broadcom Corporation (NASDAQ: BRCM) dropped 1.58%. In the after hours, BRCM spiked 7.62% after posting better than expected earnings. ProShares UltraPro Russell2000 ETF (NYSE...
-
5 Stocks for Your Watchlist
Monday, July 25, 2011 - 6:06pm | 1719( click to enlarge ) Staples, Inc. (NASDAQ:SPLS) has finally closed above its 50-day SMA moving average currently placed around levels of $15.90. This stock has just started moving higher and established a short term up-trend. Momentum indicators are slightly bullish now with RSI inching...
-
Arena Pharmaceuticals Breaks Higher; Now Up 6+%
Monday, July 25, 2011 - 2:45pm | 109Shares of Arena Pharmaceuticals (NASDAQ: ARNA) are trading higher today; currently, shares are up by 6.37%, trading at $1.67. The stock has been consolidating above the 20-day and 50-day moving averages for the past two weeks, preempting this break out. Arena Pharmaceuticals is poised to now test...
-
ISI Group Comments on Gilead Sciences
Monday, July 25, 2011 - 2:30pm | 117ISI Group provided color on Gilead Sciences (NASDAQ: GILD) regarding Gilead Sciences' upcoming earnings announcement tomorrow after market closing. In the report, ISI Group states, "While investors wait for the upcoming QUAD Phase III data readout later this quarter, the focus of the earnings call...
-
Celgene Earnings Preview: Analysts Expect Falling Revenue, Rising EPS Over Last Quarter
Monday, July 25, 2011 - 2:20pm | 506Celgene (NASDAQ: CELG) announces its next round of earnings this Thursday, July 28, 2011. Get the latest predictions in Benzinga's essential guide to the company's second quarter earnings report. Earnings and Revenue: Analysts are predicting an EPS reading of 77 cents per share and revenues of $...